• Xiangbo Shen, Eryue Qiu, Zhao Liu, Xiaopeng Zhu, and Yiqian Zeng.
• From the Department of Pulmonary and Critical Care Medicine (Shen), Jiangxi PingXiang People's Hospital, Pingxiang, Jiangxi Province, from the Department of Trauma Center (Qiu, Zhu, Zeng); and from the Department of Critical Care Medicine (Liu), Zhuzhou Central Hospital, Zhuzhou, Hunan Province, China.
• Saudi Med J. 2024 Apr 1; 45 (4): 341348341-348.

ObjectivesTo evaluate the effectiveness and safety of rivaroxaban anticoagulation in COVID-19 patients.MethodsPubMed, Embase, Cochrane Library electronic databases, and ClinicalTrials.gov were searched to identify all relevant randomized controlled trial studies from December 2019 to July 2023.ResultsA total of 6 randomized controlled trials, which included a total of 3323 patients, were considered for evaluation. Overall, short-term all-cause mortality and hospitalization rates were not significantly different between the rivaroxaban and control groups. Thrombotic events were significantly reduced in the rivaroxaban prophylaxis group compared to the placebo control group. However, the reduction in thrombotic events was not significantly different between rivaroxaban therapy and heparin or low-molecular-weight heparin (LMWH). Rivaroxaban prophylaxis and the therapeutic dose may be associated with a higher rate of overall bleeding rate, but major bleeding rates did not differ substantially.ConclusionRivaroxaban may reduce thrombotic events in COVID-19 patients, but it does not appear to have an advantage over heparin or LMWH, and it may increase the risk of bleeding.INPLASY Reg. No.: INPLASY 202370097.Copyright: © Saudi Medical Journal.

26 keywords...

hide…